BEIJING, May 26 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that the Company will participate at the 2010 Shanghai CPhI Exhibition, being held June 2-4, 2010. Sinovac's exhibition booth will be located in Hall E4, No. E4C42. At the exhibition, Sinovac will showcase its commercialized products, including its Healive, Anflu, Panflu and Panflu.1 vaccines.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We are excited to participate in the CPhI Exhibition inShanghai, where we will feature our high quality products, such as vaccines against hepatitis A and seasonal influenza. As the exhibition attracts a global audience, we look forward to meeting with current and potential new international distribution partners to explore opportunities to further advance our global distribution strategy."
The Shanghai CPhI Exhibition provides Sinovac and other exhibitors/attendees with the opportunity to gain a better understanding of the global pharmaceutical industry. In 2009, a total of 1,651 exhibitors attended the event, including 127 overseas companies from 16 countries and regions. In addition to the exhibition booths, CPhI also hosted 54 high level conferences and seminars during the event, providing exhibitors and attendees with the opportunity to further communicate and exchange the latest information in the pharmaceutical industry.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.
About CPhI Worldwide
CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. This inaugural CPhI attracted 250 visitors for the 16 exhibitors. Today this has grown to an unrivalled 24,000 industry professionals visiting some 1,500 exhibiting companies from over 125 countries. CPhI is the leading exhibition on pharmaceutical ingredients and allied industries. Each year the exhibition grows larger with exhibitors and visitors conducting significant levels of business at CPhI. Two sister events, ICSE and P-MEC now run alongside CPhI, a tripartite of events that is considered the must attend event for any individual or organisation within the pharmaceutical manufacturing community. In 2001 CPhI was launched in China. ICSE China was launched in 2005 and P-MEC China in 2006.
For more information, please contact:
Sinovac Biotech Ltd.
Amy Glynn/Stephanie Carrington
The Ruth Group
The Ruth Group
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.
For more information, please visit the Company’s website at www.sinovac.com.
Sinovac Biotech Ltd.